
Vaxcyte is seeking a Director, Clinical Medical Writing to drive and shape the medical writing processes, procedures, strategies, and document generation and maintenance. This position will lead medical writing activities and will manage contract writers and document QC experts, as well as workflows for document development in Veeva Vault. Key accountabilities include generating documents such as protocol, investigator brochure, informed consent form, pharmacy manual, manuscripts, clinical study reports, etc.), providing guidance on scientific and technical requirements for regulatory documents, contributing towards a style guide for Vaxcyte, and following best practices for authoring of key clinical regulatory documents to meet global regulatory standards. The Director, Clinical Medical Writing will develop new SOPs and templates and contribute towards existing SOPs to support the writing of clinical documents for clinical development activities.
To be successful, the incumbent will be a strong collaborator and communicator, possessing outstanding clinical writing skills and an attitude that fits our culture in a high growth, fast-paced environment.
Essential Functions:
Requirements:
Reports to: Sr. Vice President, Clinical Development
Location: San Carlos, CA or Remote Based
Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (minimum of 2-3 days per week onsite)/Remote
Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $221,000 – $258,000 (SF Bay Area). Salary ranges for non-California locations may vary.
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.